pGy2 program
ONCOLOGY

Residency Program Director
  • Tracy Wiczer, PharmD, BCOP

    • PGY2 Oncology Residency Program Director, The James Cancer Hospital at The Ohio State University
    • PGY2 Oncology, The James Cancer Hospital at The Ohio State University
    • PGY1, The Jewish Hospital-Mercy Health, Cincinnati, Ohio
    • PharmD, University of Cinicinnati
Previous Year Residents
  • Megan Fleming, PharmD

    Hematology/Oncology Pharmacist Specialist, The James Cancer Hospital
  • Lexus Frazier, PharmD

    Hematology/Oncology Pharmacist Specialist at The James Cancer Hospital
  • Samantha Musson, PharmD

    Hematology/Oncology Pharmacist Specialist at Christ Hospital in Cincinnati, Ohio
  • Shivani Prakshesh Patel, PharmD

    Clinical Pharmacist Specialist, University of Chicago Medicine
  • Pooja Kumar

    Clinical Pharmacy Specialist in Hematology/Oncology-The James Cancer Hospital Solove Research Institute
  • Alycia Hatashima

    Clinical Pharmacy Specialist, Oncology, Seattle Cancer Care Alliance
  • Dat Le

    Clinical Pharmacy Specialist, Outpatient Gastrointestinal/Neuroendocrine Cancers Clinic at Martha Morehouse
  • Delaney Wolfe

    Clinical Pharmacy Specialist, Bone Marrow Transplant, Franciscan Health, Indianapolis, IN
  • Tracelyn Freeman

    Inpatient/Outpatient BMT and Acute Leukemia, The James Cancer Hospital Solove Research Institute
  • Leylah Azali

    Outpatient Clinical Hematology Specialist, Houston Methodist Hospital
  • Danielle Murphy

    Heme/Onc Cell Therapy Clinical Pharmacy Specialist, Rush University Medical Center, Chicago
  • Kristen Nymberg

    Inpatient/Outpatient GU Medical Oncology Pharmacy Specialist, The James Cancer Hospital Solove Research Institute
  • LeeAnn Geraghty

    Clinical Hematology/Oncology Specialist Pharmacist, Norton Healthcare, Louisville, KY
  • Allison Grana

    Inpatient/Outpatient GU Medical Oncology Clinical Pharmacy Specialist, MD Anderson Cancer Center, Houston, TX
  • Brendan Rasor

    Pharmacist (Outpatient Infusion) Kettering Health Network and the Kettering Cancer Care Pavilion, Dayton OH
  • Justin Tossey

    Inpatient/Outpatient BMT and Acute Leukemia, The James Cancer Hospital Solove Research Institute

About the PGY2 Oncology Residency Program

Purpose

PGY2 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in advanced or specialized practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge incorporating both into the provision of patient care that improves medication therapy. Residents who successfully complete an accredited PGY2 pharmacy residency should possess competencies that qualify them for clinical pharmacist and/or faculty positions and position them to be eligible for attainment of board certification in that practice area (when board certification for the practice area exists).

The purpose of the PGY2 Hematology/Oncology residency is to develop specialized knowledge in the pathophysiology and management of patients with hematology and oncology disorders. This is accomplished through core rotations to strengthen hematology and oncology fundamentals as well as elective rotations with the flexibility to meet the individual’s needs.

The program is designed to develop the resident’s clinical expertise and additionally provide opportunities for teaching, research, and quality improvement. Pharmacists completing the residency will be trained as clinical specialists able to excel as an independent practitioner. The goal of the program is to become an integral member of a Hematology/Oncology multidisciplinary team in a large academic setting.

DSC_8758Residency Sites

The Ohio State University Comprehensive Cancer Center – James Cancer Hospital is ranked nationally as one of the top hospitals for cancer care, maintaining an “exceptional” rating – the highest descriptor given by the National Cancer Institute, and is the third largest cancer center in the nation.  Opened in December 2014, with 21 floors spanning 1.1 million square feet, the new James Cancer Hospital and Solove Research Institute revolutionizes the way cancer prevention and care are provided, with over 200 specialized oncologists and cancer researchers working side-by-side to unlock the mysteries of what causes cancer and, using those discoveries, transition from cancer treatment to cancer prevention.

Read More

DSC_8683

This 356-bed adult cancer clinical care facility, including a 36-bed blood and marrow transplant unit, is a member of the National Comprehensive Cancer Network, the National Cancer Institute’s National Clinical Trial Network— notably one of only four centers funded by the NCI to conduct both Phase I and II clinical trials on novel anticancer drugs, achieved Magnet® designation for excellence in patient care, and is fully accredited by the Joint Commission, the American College of Surgeons Common on Cancer and the Foundation for the Accreditation of Cellular Therapy. The center includes six outpatient chemotherapy infusion clinics, dispensing an estimate of over 75,000 doses of chemotherapy annually. The Department of Pharmacy consists of inpatient and outpatient hematology/oncology clinical specialist pharmacists, pain and palliative medicine pharmacists, anti-coagulation pharmacists, cancer informatics pharmacists, medication assistance pharmacists, and Hematology/Oncology specialty practice pharmacy residents.

The James Cancer Hospital at The Ohio State University offers a one-year postgraduate year two (PGY2) ASHP accredited oncology pharmacy residency program. The clinical pharmacy program is designed to align with our subspecialized disease specific model allowing residents the opportunity to train with clinical specialists who are experts in their subspecialty in both inpatient and ambulatory clinic setting. The program allows residents to develop their hematology/oncology knowledge base including cancer treatment, supportive care, and the role of clinical trials in this patient population. Upon completion of the program, the resident will have the skillset necessary to work as a respected member of a multi-disciplinary hematology/oncology patient care team.

KEY ROTATIONS/EXPERIENCES

The resident will complete a combination of rotations and longitudinal experiences designed around the core objectives specified by ASHP in addition to the resident’s interest.

Orientation: 4 weeks (orientation may be modified for early commit residents)

Research: 3-4 weeks

Hematology

  • Inpatient Acute Leukemia – 4 weeks
  • Bone Marrow Transplantation – 4 weeks
  • Inpatient Lymphoma – 4 weeks
  • Outpatient Hematology Clinics – Leukemia, BMT, CLL, Lymphoma and Myeloma – 4 weeks

Oncology

  • Inpatient Oncology – 4 weeks
  • Outpatient Solid Tumor Clinics
    • Outpatient Breast Cancer – 3 weeks
    • Outpatient Gastrointestinal Cancers (GI) + Melanoma (1 d/week) – 4 weeks
    • Outpatient Lung (Thoracic) – 3 weeks
    • Outpatient Genitourinary (GU) – 3 weeks
    • Outpatient Gynecology Oncology (Gyn Onc) – 1 d/week during GU/Thoracic rotation

Clinical trials unit (CTU): 1 week

Pain and Palliative: 2 weeks

Required Longitudinal

  • Administration/Medication Assistance
  • Medication Safety
  • Teaching
  • Research/MUE

Electives: 4-8 weeks, experiences can be 1-4 weeks in length, electives not listed below can be arranged on specific request

  • Anything in required repeated
  • Inpatient leukemia/transplant
  • Inpatient CLL/MM/misc heme
  • Inpatient benign heme
  • Outpatient Leukemia/BMT
  • Outpatient Head & Neck/Sarcoma
  • Outpatient Melanoma
  • Outpatient Gynecology Oncology
  • Outpatient Neurooncology
  • Oncology Administration
  • Informatics
  • Infectious Diseases
  • Pediatric Hematology/Oncology (Nationwide Children’s Hospital)

Key Preceptors

Learn more about the Hematology/Oncology key preceptors:

Read More

INPATIENT/OUTPATIENT HEMATOLOGY
  • Jessica Loborec, PharmD, BCOP
    Outpatient Multiple Myeloma
  • Rebecca Evers, PharmD, BCOP
    Outpatient Multiple Myeloma and Lymphoma
  • Pooja Kumar, PharmD, BCOP
    Inpatient/Outpatient BMT and Acute Leukemia
  • Tracelyn Freeman, PharmD, BCOP
    Inpatient/Outpatient BMT and Acute Leukemia
  • Megan Fleming, PharmD
    Inpatient/Outpatient BMT and Acute Leukemia
  • Natalia Hartzler, PharmD, BCOP
    Inpatient/Outpatient BMT and Acute Leukemia
  • Jeremy Sen, PharmD, BCOP
    Inpatient/Outpatient BMT and Acute Leukemia
  • Justin Tossey, PharmD, BCOP
    Inpatient/Outpatient BMT and Acute Leukemia
  • Ally Waller, PharmD, BCOP
    Inpatient/Outpatient BMT and Acute Leukemia
  • Caitlyn Crawford, PharmD, BCOP
    Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma
  • Lindsay Rosen, PharmD, BCOP
    Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma
  • Jordan Lundberg, PharmD, BCOP
    Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma
  • Tracy Wiczer, PharmD, BCOP
    Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma

 

INPATIENT/OUTPATIENT ONCOLOGY
  • Matt Arango, PharmD, BCOP
    Outpatient Gastrointestinal Cancer
  • Dan Kendzierski, PharmD, BCOP
    Outpatient Gastrointestinal Cancer
  • Dat Le, PharmD, BCOP
  • Outpatient Gastrointestinal Cancer/Neuroendocrine
  • Brianna Archambeau, PharmD, BCOP
    Inpatient Medical Oncology
  • Andrew Stone, PharmD, BCPS
  • Inpatient Medical Oncology
  • Michael Berger, PharmD, BCOP
    Outpatient Breast Cancer
  • Stephanie Collins, PharmD, BCOP
    Outpatient Breast Cancer
  • Craig Vargo, PharmD, BCOP
    Outpatient Breast Cancer
  • Eric Fela, PharmD, BCOP
    Outpatient Gynecologic Cancers
  • Ambar Khan, PharmD, BCOP
  • Outpatient Gynecologic Cancers
  • Megan Hinkley, PharmD, BCOP
    Outpatient Genitourinary Cancers, Lung Cancer
  • Sarah Hoffman, PharmD, BCOP
    Outpatient Head & Neck Cancer/Sarcoma
  • Gretchen Pardo, PharmD, BCOP
    Inpatient Medical Oncology/Outpatient Melanoma
  • Kristen Nymberg, PharmD, BCOP
    Inpatient Medical Oncology/Outpatient Genitourinary Cancers
  • Lauren Ledbetter, PharmD, BCOP
  • Inpatient Medical Oncology/Outpatient Genitourinary Cancers
  • Michael Smith, PharmD, BCOP
    Outpatient Lung Cancer
  • Greg Samijlenko, PharmD, BCPS, BCOP
    Outpatient Neuro-oncology

 

HEMATOLOGY/ONCOLOGY FLOATS
  • Tyler Dickerson, PharmD, BCOP
    Hematology/Oncology Float
  • Allison Reed, PharmD, BCOP
  • Hematology/Oncology Float
  • Jaelyn Westfield, PharmD, BCOP
  • Hematology/Oncology Float
  • Tommy Montgomery, PharmD, BCOP
  • Hematology/Oncology Float
  • Lexus Frazier, PharmD
  • Hematology/Oncology Float
HEMATOLOGY/ONCOLOGY ANTICOAGULATION
  • Paige Erdeljac, PharmD, BCACP
    Hematology/Oncology Anticoagulation
  • Stephanie Yager, PharmD, BCACP
    Hematology/Oncology Anticoagulation
PAIN AND PALLIATIVE MEDICINE
  • Jessica Hirsch, PharmD
    Palliative Medicine
  • Gary Houchard, PharmD
    Palliative Medicine
  • Justin Kullgren, PharmD, CPE
    Palliative Medicine
  • Kyle Quirk, PharmD
    Palliative Medicine
  • Maureen Saphire, PharmD, BCGP, CDP
    Palliative Medicine
OTHER HEMATOLOGY AND ONCOLOGY PRECEPTORS
  • Amber Hartman, PharmD
    Medication Safety
  • Naomi Digiantonio, PharmD, BCPS
    Generalist Pharmacist, Clinical Trials Unit
  • Justin Osorio, PharmD, BCPS
    Generalist Pharmacist, Inpatient Benign Hematology
  • Jacquelyn Williams, PharmD
    Generalist Pharmacist, Inpatient Benign Hematology
ADMINISTRATION
  • Hallie Barr, PharmD, BCOP
    Pharmacy Manager, Investigational Drug Services
  • Janinah Barreto, PharmD, MS, CPHIMS
    Assistant Director, Pharmacy Informatics Clinical Applications
  • Mitch Dorn, PharmD, MS
    Associate Director, Central Pharmacies
  • Morgan Forshay, PharmD, MS, BCPS
    Pharmacy Manager, Inpatient Oncology
  • Sarah Hudson-Disalle, PharmD
    Pharmacy Manager, Prior Authorization
  • Julie Kennerly-Shah, PharmD, MS, MHA, BCPS
    Associate Director, Cancer Pharmacy Services
  • Ben Lopez, PharmD, MS, MHA, BCPS
    Director, Enterprise Operations
  • Stephen Polley, PharmD, MPA, MS, BCPS
    Assistant Director, Cancer Pharmacy Services
  • Heather Armbruster, PharmD, BCOP
    Pharmacy Manager, Clinical Outpatient Services
  • Emily Dotson, PharmD, BCOP
    Pharmacy Manager, Clinical Inpatient Services

Selected RESIDENT RESEARCH

  • Comparison of docetaxel hypersensitivity reaction rates between aggressive pre-medication strategy versus conventional strategy. Fleming M
  • Plasmablastic lymphoma treated with EPOCH with or without bortezomib. Frazier L
  • Evaluation of trifluridine/tipiracil with and without bevacizumab in patients with previously treated metastatic colorectal cancer. Musson S
  • Efficacy and tolerability of hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma, a single center retrospective review. Patel S
  •  

Benefits and Additional Requirements

Application Deadline:  January 2

Start Date: July 1

Annual Salary – $48,500

Vacation Days – 10 Days

Staffing Requirement – 20 weekends per year

Completion of a Major Research Project

TEACHING OPPORTUNITIES

Download PDF